Luis Quintino

Affiliations: 
Wallenberg neuroscience center 
Area:
Gene therapy, parkinsons disease
Google:
"Luis Quintino"
Mean distance: 17.37 (cluster 11)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Quintino L, Avallone M, Brännstrom E, et al. (2018) GDNF-mediated rescue of the nigrostriatal system depends on the degree of degeneration. Gene Therapy
Quintino L, Namislo A, Davidsson M, et al. (2018) Destabilizing Domains Enable Long-Term and Inert Regulation of GDNF Expression in the Brain. Molecular Therapy. Methods & Clinical Development. 11: 29-39
Davidsson M, Díaz-Fernández P, Torroba M, et al. (2018) Molecular barcoding of viral vectors enables mapping and optimization of mRNA trans-splicing. Rna (New York, N.Y.)
Breger L, Wettergren EE, Quintino L, et al. (2016) Regulated Gene Therapy. Methods in Molecular Biology (Clifton, N.J.). 1382: 57-66
Wettergren EE, Quintino L, Manfré G, et al. (2014) Gene therapy for Parkinson’s disease Neuromethods. 82: 181-191
Quintino L, Manfré G, Wettergren EE, et al. (2013) Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 2169-80
Quintino L, Baudet A, Larsson J, et al. (2013) FACS binding assay for analysing GDNF interactions. Journal of Neuroscience Methods. 218: 25-8
Ã…kerblom M, Sachdeva R, Quintino L, et al. (2013) Visualization and genetic modification of resident brain microglia using lentiviral vectors regulated by microRNA-9. Nature Communications. 4: 1770
Lindgren N, Francardo V, Quintino L, et al. (2012) A model of GDNF gene therapy in mice with 6-Hydroxydopamine lesions: time course of Neurorestorative effects and ERK1/2 activation. Journal of Parkinson's Disease. 2: 333-48
Wettergren EE, Gussing F, Quintino L, et al. (2012) Novel disease-specific promoters for use in gene therapy for Parkinson's disease. Neuroscience Letters. 530: 29-34
See more...